E-LIB Suche - Ergebnisse für: Bannerji, Rajat

1

Molecular assessment of intratumoral immune cell subsets an..:

Brouwer-Visser, Jurriaan ; Fiaschi, Nathalie ; Deering, Raquel P...
Journal for ImmunoTherapy of Cancer. 12 (2024) 3 - p. e008338 , 2024

Link: https://doi.org/10.1136/..

2

Polatuzumab vedotin, venetoclax, and an anti‐CD20 monoclona..:

Yuen, Sam ; Phillips, Tycel J. ; Bannerji, Rajat...
American Journal of Hematology. , 2024

Link: https://doi.org/10.1002/..

3

IBCL-485 A Phase III, Randomized, Double-Blind, Study of Ta..:

Salles, Gilles ; Shah, Harsh ; Leonard, John P....
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S454-S455 , 2023

Link: https://doi.org/10.1016/..

4

Targeting MCL‐1 and BCL‐2 with polatuzumab vedotin and vene..:

Lasater, Elisabeth A. ; Amin, Dhara N. ; Bannerji, Rajat...
American Journal of Hematology. 98 (2023) 3 - p. 449-463 , 2023

Link: https://doi.org/10.1002/..

5

POSTER: IBCL-485 A Phase III, Randomized, Double-Blind, Stu..:

Salles, Gilles ; Shah, Harsh ; Leonard, John P....
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S209 , 2023

Link: https://doi.org/10.1016/..

6

Treatment Discontinuation Patterns for Patients With Chroni..:

Shadman, Mazyar ; Manzoor, Beenish S. ; Sail, Kavita...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) 7 - p. 515-526 , 2023

Link: https://doi.org/10.1016/..

7

Pembrolizumab plus dinaciclib in patients with hematologic ..:

Gregory, Gareth P. ; Kumar, Shaji ; Wang, Ding...
Blood Advances. 6 (2022) 4 - p. 1232-1242 , 2022

Link: https://doi.org/10.1182/..

8

Fixed-duration ibrutinib plus venetoclax for first-line tre..:

Tam, Constantine S. ; Allan, John N. ; Siddiqi, Tanya...
Blood. 139 (2022) 22 - p. 3278-3289 , 2022

Link: https://doi.org/10.1182/..

9

Immunotherapies Old and New: Hematopoietic Stem Cell Transp..:

Doraiswamy, Anupama ; Shah, Mansi R. ; Bannerji, Rajat
Current Hematologic Malignancy Reports. 16 (2021) 1 - p. 72-81 , 2021

Link: https://doi.org/10.1007/..

10

Impact of Insurance Status on Survival Outcomes in Adults W..:

Krakora, Rebecca ; Shih, Weichung ; Popli, Pallvi...
Clinical Lymphoma Myeloma and Leukemia. 20 (2020) 11 - p. e890-e896 , 2020

Link: https://doi.org/10.1016/..

11

Phase 1 safety, pharmacokinetic and pharmacodynamic study o..:

Mita, Monica M ; Mita, Alain C ; Moseley, Jennifer L...
British Journal of Cancer. 117 (2017) 9 - p. 1258-1268 , 2017

Link: https://doi.org/10.1038/..

12

Randomized Phase II Trial of the Cyclin-Dependent Kinase In..:

Mita, Monica M. ; Joy, Anil A. ; Mita, Alain...
Clinical Breast Cancer. 14 (2014) 3 - p. 169-176 , 2014

Link: https://doi.org/10.1016/..

13

Randomized phase 2 study of the cyclin-dependent kinase inh..:

Stephenson, Joe J. ; Nemunaitis, John ; Joy, Anil A....
Lung Cancer. 83 (2014) 2 - p. 219-223 , 2014

Link: https://doi.org/10.1016/..

14

Clinical and laboratory studies of the novel cyclin-depende..:

Gojo, Ivana ; Sadowska, Mariola ; Walker, Alison...
Cancer Chemotherapy and Pharmacology. 72 (2013) 4 - p. 897-908 , 2013

Link: https://doi.org/10.1007/..

15

A first-in-human, phase 1, dose-escalation study of dinacic..:

Nemunaitis, John J ; Small, Karen A ; Kirschmeier, Paul...
Journal of Translational Medicine. 11 (2013) 1 - p. 259 , 2013

Link: https://doi.org/10.1186/..